Monthly elebsiran plus tobevibart achieved undetectable HDV RNA with ALT normalization in 44% of patients at week 48 in the pivotal phase 3 ECLIPSE 1 trial.
|Articles|April 25, 2023
World Immunization Week: The Latest Infectious Disease Vaccine Updates
Author(s)Nina Cosdon
The last week in April is World Immunization Week, and we're recapping the most recent and significant developments in infectious disease vaccines.
Advertisement
Celebrated in the last week of April, World Immunization Week highlights the importance of
"The ultimate goal of World Immunization Week is for more people—and their communities—to be protected from vaccine-preventable diseases," the World Health Organization
For 2023, the theme of World Immunization Week is The Big Catch-Up, emphasizing the urgency of ensuring children and other individuals who missed routine vaccinations during the COVID-19 pandemic are adequaltely protected against illness, disability, and death.
Contagion rounded up our top 5 stories on recent vaccine developments to raise awareness for World Immunization Week, encompassing the progress and setbacks in infectious disease vaccinations.
Advertisement
Related to this article
Deborah Fuller, PhD, provides commentary around the data, and advantages of the technology.
Charles M. Walworth, MD, of Labcorp discusses a new hepatitis D reflex pathway, internal data showing 8.3% of HBsAg-positive patients screened for HDV, and lessons from hepatitis C reflex testing.
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
CDC reports 10,772 confirmed Ebola cases and 5234 deaths, making this the second-largest outbreak on record. Kenya and Nigeria have reported cases.
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with Staphylococcus aureus Bacteremia (SAB). This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline.
New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.
Advertisement
Advertisement